Use of Aromatase Inhibitors in Large Cell Calcifying Sertoli Cell Tumors: Effects on Gynecomastia, Growth Velocity, and Bone Age.
Conclusions: Patients with LCCSCT benefit from aromatase inhibitor therapy with reduction and/or elimination of gynecomastia and slowing of linear growth and bone age advancement. Further study of long-term outcomes and safety monitoring are needed but these preliminary data suggest that mammoplasty and/or orchiectomy may be foregone in light of the availability of proper medical therapy.
PMID: 25226294 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Crocker MK, Gourgari E, Lodish M, Stratakis CA Tags: J Clin Endocrinol Metab Source Type: research
More News: Boys | Children | Endocrinology | Estradiol | Gynecomastia | Hormones | Sertoli Cell Tumor | Study | Ultrasound